Arkansas § 20-15-2106 Costs - Definition

Arkansas Statutes

§ 20-15-2106 — Costs - Definition

Arkansas § 20-15-2106

Title20

This text of Arkansas § 20-15-2106 (Costs - Definition) is published on Counsel Stack Legal Research, covering Arkansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Ark. Code Ann. § 20-15-2106 (2026).

Text

(a)A manufacturer of an investigational drug, biological product, or device may:

(1)Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation; or (2) (A) Require an eligible patient to pay the costs associated with the manufacture of the investigational drug, biological product, or device.

(B)As used in this section, "costs associated with the manufacture of the investigational drug, biological product, or device" means the actual out-of-pocket costs incurred in providing the investigational drug, biological product, or device to the patient in the specific case.

(b)If a patient dies while being treated by an investigational drug, biological product, or device, the patient's heirs are not liable for any outstanding debt to the

Free access — add to your briefcase to read the full text and ask questions with AI

(a) A manufacturer of an investigational drug, biological product, or device may: (1) Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation; or (2) (A) Require an eligible patient to pay the costs associated with the manufacture of the investigational drug, biological product, or device. (B) As used in this section, "costs associated with the manufacture of the investigational drug, biological product, or device" means the actual out-of-pocket costs incurred in providing the investigational drug, biological product, or device to the patient in the specific case. (b) If a patient dies while being treated by an investigational drug, biological product, or device, the patient's heirs are not liable for any outstanding debt to the manufacturer related to the investigational drug, biological product, or device.